主页 > 医学前沿 >
【medical-news】波生坦+伟哥改善肺动脉高压患者的
By Martha Kerr
CHICAGO (Reuters Health) Oct 26 - Data from a large registry presented here this week at CHEST 2007, the 73rd annual international scientific assembly of the American College of Chest Physicians, show that combination therapy for pulmonary arterial hypertension (PAH) with sildenafil and bosentan improves hemodynamics and may delay progression of disease.
The Endothelin Antagonist Trial in Mildly Symptomatic PAH Patients (EARLY) involved 29 patients with PAH on sildenafil at baseline out of a total of 185 patients in the EARLY registry. Patients were randomized to bosentan, 62.5 mg twice daily for four weeks then 125 mg twice a day, or placebo in addition to sildenafil.
Dr. Nazzareno Galie of the University of California at San Diego presented the data after six months of follow-up.
At baseline, patients had a six-minute walk-test that was less than 80% of expected. Mean baseline pulmonary vascular resistance (PVR) was approximately 1,000 dynes/sec/cm-5. With combination therapy, that fell to approximately 650 dynes/sec/cm-5, Dr. Galie reported.
After six months, there was a 20% reduction in PVR in patients on combination therapy compared with those on sildenafil alone. Median improvement in six-minute walk-test was 5 meters, which did not reach statistical significance.
Dr. Galie said there appeared to be "a delay in clinical worsening" with the addition of bosentan.
"Combination therapy is a new concept," Dr. Galie told Reuters Health. "The addition of bosentan was safe and it induces an acute hemodynamic improvement."
Whether sildenafil or bosentan is started first doesn't matter when combination therapy is required, Dr. Galie said. "The effect is bidirectional," he said.
For patients whose disease is still not well-controlled, studies are underway investigating the addition of a third agent, the intravenous prostanoid epoprostenol.
http://www.medscape.com/viewarticle/564975 Bosentan Plus Sildenafil Improves Hemodynamics in PAH
波生坦联合伟哥改善肺动脉高压血流动力学
By Martha Kerr
CHICAGO (Reuters Health) Oct 26 - Data from a large registry presented here this week at CHEST 2007, the 73rd annual international scientific assembly of the American College of Chest Physicians, show that combination therapy for pulmonary arterial hypertension (PAH) with sildenafil and bosentan improves hemodynamics and may delay progression of disease.
芝加哥（路透社健康） 10月26日-在本周举行的2007年美国胸科医师学会第73届国际科学年会上，一项大型注册研究的数据表明，西地那非和波生坦联合治疗肺动脉高压（PAH）可改善血流动力学，并延缓疾病进展。
The Endothelin Antagonist Trial in Mildly Symptomatic PAH Patients (EARLY) involved 29 patients with PAH on sildenafil at baseline out of a total of 185 patients in the EARLY registry. Patients were randomized to bosentan, 62.5 mg twice daily for four weeks then 125 mg twice a day, or placebo in addition to sildenafil.
轻度肺动脉高压患者内皮素拮抗剂试验(EARLY) 共登记185例PAH患者，选择基线状态使用西地那非的29例患者进行研究。在西地那非治疗的基础上，这些患者被随机分为波生坦组（ 62.5毫克，每日两次，连续4周，然后125毫克，每日两次）或安慰剂组。
Dr. Nazzareno Galie of the University of California at San Diego presented the data after six months of follow-up.
圣地亚哥加州大学Nazzareno galie博士介绍了随访6个月后的数据。
At baseline, patients had a six-minute walk-test that was less than 80% of expected. Mean baseline pulmonary vascular resistance (PVR) was approximately 1,000 dynes/sec/cm-5. With combination therapy, that fell to approximately 650 dynes/sec/cm-5, Dr. Galie reported.
Galie博士在报告上称，基线状态时进行六分钟步行试验的患者不到预期的80 ％。基线平均肺血管阻力（ PVR）为1000 dynes/sec/cm-5 。经过联合治疗，PVR下降到650 dynes/sec/cm-5左右。
After six months, there was a 20% reduction in PVR in patients on combination therapy compared with those on sildenafil alone. Median improvement in six-minute walk-test was 5 meters, which did not reach statistical significance.
6个月后，接受联合治疗的患者与单用西地那非的患者相比，PVR下降20 ％。 六分钟步行试验改善的中位数是5米，没有达到统计学意义。
Dr. Galie said there appeared to be "a delay in clinical worsening" with the addition of bosentan.
Galie博士说，加用波生坦后，疾病的临床恶化得到延缓。
"Combination therapy is a new concept," Dr. Galie told Reuters Health. "The addition of bosentan was safe and it induces an acute hemodynamic improvement."
"联合治疗是一个全新的概念， "Galie博士告诉路透社。 "加用波生坦是安全的，它可以引起急性血流动力学改善。 "
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-06 17:11
医学,生命科学网